Bayer Inc. v. Cobalt Pharmaceuticals Company, 2017 FC 775 (Drospirenone*)
Justice Fothergill - 2017-08-18
Read full decision. Automatically generated summary:
[Note: Decision is from 2017 but only published online recently] The Defendants have brought motions to strike portions of the Plaintiffs’ Statements of Issues. In the alternative, the Defendants request particulars. A Statement of Issues must be read within the broader context of the proceedings as a whole. Viewed in this light, the disputed portions of the Statements of Issues disclose reasonable causes of action. They are sufficiently clear to allow for intelligent responses, and further particulars are not required at this time. The motions are therefore dismissed. Given the legitimacy of some of the concerns raised by Apotex and Cobalt regarding overbreadth and ambiguity in the Statements of Issues, no costs are awarded.
Decision relates to:
- T-1368-14 - BAYER INC. ET AL v. APOTEX INC.
- T-1379-13 - BAYER INC. ET AL v. COBALT PHARMACEUTICALS COMPANY
- T-1468-13 - BAYER INC. ET AL v. APOTEX INC.